{"id":"W2119967200","doi":"10.1007/s12032-011-0016-8","title":"Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement","year":2011,"lang":"en","type":"review","venue":"Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Hospital Foundation","funders":"Novartis Pharma; Sanofi; Bayer HealthCare; GlaxoSmithKline; Pfizer","keywords":"Sunitinib; Sorafenib; Temsirolimus; Everolimus; Medicine; Pazopanib; Renal cell carcinoma; Bevacizumab; Internal medicine; Oncology; Axitinib; Pharmacology; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002028459,0.0006708276,0.002362545,0.0009514119,0.0001771796,0.00118039,0.001301259,0.001639171,0.002167632],"category_scores_gemma":[0.00147733,0.0003299425,0.001256713,0.001184609,0.0004566285,0.001414287,0.0005012192,0.002034615,0.0007973968],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008809784,"about_ca_system_score_gemma":0.001334057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001362155,"about_ca_topic_score_gemma":0.002849666,"domain_scores_codex":[0.9995647,0.0001009908,0.00009828409,0.00006961043,0.0001322923,0.00003410087],"domain_scores_gemma":[0.9989773,0.0006705824,0.0001413593,0.00002000925,0.0001674883,0.00002333004],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002528372,0.00008651023,0.0001702077,0.0294819,0.0003398758,0.0001385151,0.00005448494,0.0008560251,0.001596814,0.003998863,0.0159543,0.9470696],"study_design_scores_gemma":[0.0002668919,0.0004430964,0.001727219,0.02414352,0.001217266,0.001254423,0.0001033062,0.0004685863,0.001609718,0.004307871,0.964405,0.00005306025],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001920631,0.9979604,0.0002367635,0.0006805212,0.0001832041,0.0000118047,0.00002565882,0.000003090692,0.0007065208],"genre_scores_gemma":[0.002368614,0.9953322,0.0006814689,0.0007840148,0.0002215505,0.00002382485,0.00004415895,0.000002290125,0.0005418779],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002362545,"threshold_uncertainty_score":0.0107277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07924066159462474,"score_gpt":0.3525873089175282,"score_spread":0.2733466473229035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}